Does the media favor EBS or JNJ?

In the previous week, Johnson & Johnson had 42 more articles in the media than Emergent Biosolutions. MarketBeat recorded 61 mentions for Johnson & Johnson and 19 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 0.99 beat Emergent Biosolutions' score of 0.43 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 2 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Johnson & Johnson 42 Very Positive mention(s) 10 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to MAZE or EBS?

In the previous week, Emergent Biosolutions had 18 more articles in the media than Maze Therapeutics. MarketBeat recorded 19 mentions for Emergent Biosolutions and 1 mentions for Maze Therapeutics. Emergent Biosolutions' average media sentiment score of 0.43 beat Maze Therapeutics' score of 0.00 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 2 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VIR or EBS?

In the previous week, Emergent Biosolutions had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 19 mentions for Emergent Biosolutions and 13 mentions for Vir Biotechnology. Emergent Biosolutions' average media sentiment score of 0.43 beat Vir Biotechnology's score of 0.33 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Emergent Biosolutions 2 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GLUE or EBS?

In the previous week, Emergent Biosolutions had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 19 mentions for Emergent Biosolutions and 18 mentions for Monte Rosa Therapeutics. Emergent Biosolutions' average media sentiment score of 0.43 beat Monte Rosa Therapeutics' score of 0.04 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Emergent Biosolutions 2 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AVBP or EBS?

In the previous week, Emergent Biosolutions had 17 more articles in the media than ArriVent BioPharma. MarketBeat recorded 19 mentions for Emergent Biosolutions and 2 mentions for ArriVent BioPharma. Emergent Biosolutions' average media sentiment score of 0.43 beat ArriVent BioPharma's score of 0.00 indicating that Emergent Biosolutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 2 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Emergent Biosolutions (EBS) Competitors

$4.46 -0.38 (-7.85%)

As of 03:58 PM Eastern

Compare

EBS vs. JNJ, MAZE, VIR, GLUE, and AVBP

Should you buy Emergent Biosolutions stock or one of its competitors? Emergent Biosolutions's main competitors and comparable companies include Johnson & Johnson (JNJ), Maze Therapeutics (MAZE), Vir Biotechnology (VIR), Monte Rosa Therapeutics (GLUE), and ArriVent BioPharma (AVBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Emergent Biosolutions compare to Johnson & Johnson?

Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Johnson & Johnson has a net margin of 21.48% compared to Emergent Biosolutions' net margin of -22.95%. Johnson & Johnson's return on equity of 32.42% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	16.35%	6.17%
Johnson & Johnson	21.48%	32.42%	13.35%

78.4% of Emergent Biosolutions shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 6.0% of Emergent Biosolutions shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Johnson & Johnson had 42 more articles in the media than Emergent Biosolutions. MarketBeat recorded 61 mentions for Johnson & Johnson and 19 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 0.99 beat Emergent Biosolutions' score of 0.43 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	2 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Johnson & Johnson	42 Very Positive mention(s)	10 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Emergent Biosolutions has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.30M	0.31	$52.60M	-$3.55	N/A
Johnson & Johnson	$97.93B	6.42	$26.80B	$8.63	30.22

Emergent Biosolutions currently has a consensus target price of $10.00, suggesting a potential upside of 124.22%. Johnson & Johnson has a consensus target price of $268.22, suggesting a potential upside of 2.84%. Given Emergent Biosolutions' higher probable upside, equities research analysts plainly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Johnson & Johnson beats Emergent Biosolutions on 13 of the 17 factors compared between the two stocks.

How does Emergent Biosolutions compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Maze Therapeutics has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Emergent Biosolutions	-22.95%	16.35%	6.17%

In the previous week, Emergent Biosolutions had 18 more articles in the media than Maze Therapeutics. MarketBeat recorded 19 mentions for Emergent Biosolutions and 1 mentions for Maze Therapeutics. Emergent Biosolutions' average media sentiment score of 0.43 beat Maze Therapeutics' score of 0.00 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	2 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

Maze Therapeutics presently has a consensus price target of $66.00, indicating a potential upside of 141.94%. Emergent Biosolutions has a consensus price target of $10.00, indicating a potential upside of 124.22%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Maze Therapeutics is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

78.4% of Emergent Biosolutions shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Emergent Biosolutions has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.01	-$131.12M	-$2.53	N/A
Emergent Biosolutions	$742.30M	0.31	$52.60M	-$3.55	N/A

Summary

Emergent Biosolutions beats Maze Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Emergent Biosolutions compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Vir Biotechnology has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

In the previous week, Emergent Biosolutions had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 19 mentions for Emergent Biosolutions and 13 mentions for Vir Biotechnology. Emergent Biosolutions' average media sentiment score of 0.43 beat Vir Biotechnology's score of 0.33 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Emergent Biosolutions	2 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Emergent Biosolutions has a net margin of -22.95% compared to Vir Biotechnology's net margin of -638.88%. Emergent Biosolutions' return on equity of 16.35% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Emergent Biosolutions	-22.95%	16.35%	6.17%

Emergent Biosolutions has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	21.94	-$437.99M	-$1.86	N/A
Emergent Biosolutions	$742.30M	0.31	$52.60M	-$3.55	N/A

Vir Biotechnology currently has a consensus target price of $20.63, indicating a potential upside of 132.00%. Emergent Biosolutions has a consensus target price of $10.00, indicating a potential upside of 124.22%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Emergent Biosolutions beats Vir Biotechnology on 11 of the 17 factors compared between the two stocks.

How does Emergent Biosolutions compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Emergent Biosolutions has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	10.91	-$38.63M	-$1.76	N/A
Emergent Biosolutions	$742.30M	0.31	$52.60M	-$3.55	N/A

In the previous week, Emergent Biosolutions had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 19 mentions for Emergent Biosolutions and 18 mentions for Monte Rosa Therapeutics. Emergent Biosolutions' average media sentiment score of 0.43 beat Monte Rosa Therapeutics' score of 0.04 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Emergent Biosolutions	2 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monte Rosa Therapeutics presently has a consensus price target of $28.50, indicating a potential upside of 80.15%. Emergent Biosolutions has a consensus price target of $10.00, indicating a potential upside of 124.22%. Given Emergent Biosolutions' higher possible upside, analysts plainly believe Emergent Biosolutions is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Emergent Biosolutions has a net margin of -22.95% compared to Monte Rosa Therapeutics' net margin of -560.85%. Emergent Biosolutions' return on equity of 16.35% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Emergent Biosolutions	-22.95%	16.35%	6.17%

Monte Rosa Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Emergent Biosolutions beats Monte Rosa Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Emergent Biosolutions has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Emergent Biosolutions	$742.30M	0.31	$52.60M	-$3.55	N/A

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Emergent Biosolutions had 17 more articles in the media than ArriVent BioPharma. MarketBeat recorded 19 mentions for Emergent Biosolutions and 2 mentions for ArriVent BioPharma. Emergent Biosolutions' average media sentiment score of 0.43 beat ArriVent BioPharma's score of 0.00 indicating that Emergent Biosolutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	2 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma presently has a consensus price target of $44.83, indicating a potential upside of 44.67%. Emergent Biosolutions has a consensus price target of $10.00, indicating a potential upside of 124.22%. Given Emergent Biosolutions' higher possible upside, analysts plainly believe Emergent Biosolutions is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

ArriVent BioPharma has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Emergent Biosolutions	-22.95%	16.35%	6.17%

ArriVent BioPharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Summary

Emergent Biosolutions beats ArriVent BioPharma on 10 of the 16 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EBS vs. The Competition

Export

Metric	Emergent Biosolutions	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$230.12M	$3.72B	$7.06B	$24.19B
Dividend Yield	N/A	3.76%	2.58%	3.69%
P/E Ratio	-1.26	9.13	269.75	29.08
Price / Sales	0.31	1,274.20	652.34	13.90
Price / Cash	1.32	44.95	28.89	19.37
Price / Book	0.45	17.66	11.27	4.91
Net Income	$52.60M	-$13.25M	$3.45B	$1.06B
7 Day Performance	-39.77%	5.36%	3.56%	1.30%
1 Month Performance	-44.35%	-1.74%	-0.58%	2.29%
1 Year Performance	-47.84%	61.36%	77.52%	19.89%

Emergent Biosolutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EBS Emergent Biosolutions	2.2835 of 5 stars	$4.46 -7.9%	$10.00 +124.2%	-43.3%	$230.12M	$742.30M	N/A	2,420	Earnings Report Analyst Forecast Gap Down High Trading Volume
JNJ Johnson & Johnson	4.5801 of 5 stars	$254.54 -0.7%	$267.48 +5.1%	+49.4%	$617.78B	$97.93B	29.49	138,200	Trending News Insider Trade
MAZE Maze Therapeutics	1.6703 of 5 stars	$27.33 +1.5%	$66.00 +141.5%	+118.0%	$1.49B	$167.50M	N/A	121
VIR Vir Biotechnology	2.5791 of 5 stars	$8.90 +2.8%	$20.88 +134.6%	+105.1%	$1.46B	$68.56M	N/A	580	Earnings Report Analyst Upgrade
GLUE Monte Rosa Therapeutics	2.9273 of 5 stars	$15.38 -6.9%	$30.67 +99.4%	+262.6%	$1.40B	$123.67M	N/A	90	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EBS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, MAZE, VIR, GLUE, and AVBP

How does Emergent Biosolutions compare to Johnson & Johnson?

Summary

How does Emergent Biosolutions compare to Maze Therapeutics?

Summary

How does Emergent Biosolutions compare to Vir Biotechnology?

Summary

How does Emergent Biosolutions compare to Monte Rosa Therapeutics?

Summary

How does Emergent Biosolutions compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, MAZE, VIR, GLUE, and AVBP

How does Emergent Biosolutions compare to Johnson & Johnson?

Is EBS or JNJ more profitable?

Do institutionals and insiders believe in EBS or JNJ?

Does the media favor EBS or JNJ?

Which has more risk and volatility, EBS or JNJ?

Which has higher earnings and valuation, EBS or JNJ?

Do analysts prefer EBS or JNJ?

Summary

How does Emergent Biosolutions compare to Maze Therapeutics?

Is MAZE or EBS more profitable?

Does the media refer more to MAZE or EBS?

Which has more risk and volatility, MAZE or EBS?

Do analysts rate MAZE or EBS?

Do institutionals & insiders have more ownership in MAZE or EBS?

Which has better earnings & valuation, MAZE or EBS?

Summary

How does Emergent Biosolutions compare to Vir Biotechnology?

Which has more risk and volatility, VIR or EBS?

Does the media refer more to VIR or EBS?

Is VIR or EBS more profitable?

Which has better earnings & valuation, VIR or EBS?

Do analysts recommend VIR or EBS?

Do insiders & institutionals have more ownership in VIR or EBS?

Summary

How does Emergent Biosolutions compare to Monte Rosa Therapeutics?

Which has better earnings & valuation, GLUE or EBS?

Does the media refer more to GLUE or EBS?

Do analysts recommend GLUE or EBS?

Is GLUE or EBS more profitable?

Which has more volatility & risk, GLUE or EBS?

Do institutionals and insiders believe in GLUE or EBS?

Summary

How does Emergent Biosolutions compare to ArriVent BioPharma?

Which has preferable earnings and valuation, AVBP or EBS?

Do institutionals and insiders believe in AVBP or EBS?

Does the media refer more to AVBP or EBS?

Do analysts recommend AVBP or EBS?

Is AVBP or EBS more profitable?

Which has more risk & volatility, AVBP or EBS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools